IL2 and neoplasm: Evaluating data from a cohort of patients treated with high doses of IL-2, it was found that when the higher-affinity genotypes for FCGR2A, FCGR3A, and FCGR2C were considered together, they were associated with increased tumor shrinkage and prolonged survival [194].